Full text is available at the source.
Abstract
Therapeutic monoclonal antibodies may offer a targeted strategy for managing diabetic kidney disease.
- Diabetic kidney disease is a leading cause of end-stage kidney disease.
- Current treatments involve renin-angiotensin system blockade and other medications, but challenges remain.
- Monoclonal antibodies could target specific pathways related to inflammation, fibrosis, metabolism, and vascular issues in diabetic kidney disease.
- The review discusses the mechanistic rationale and clinical evidence supporting antibody-based therapies.
- Translational barriers and future prospects for these therapies are also examined.
Simplified